Orca Health has had quite a year. Launching their first app in in 2010, they now have a suite of ten apps with–we are promised–even more on the way. By combining stellar art work, three-dimensional interactive graphics and high-end native programming for the iPad, they have created and may well be en route to cornering the market for perioperative patient education apps.
Recent milestones for the company include winning the startup competition at Health 2.0 Europe, having two apps, EyeDecide & FootDecide, included in the iTunes App Store’s Apps for Healthcare Professionals. Until recently, Orca Health’s EyeDecide was ranked as the #1 downloaded free medical app on the App Store, and three other other apps (FaceDecide, BreastDecide & ENTDecide) are in the Top 25. To top it off, the iTunes App Store just included EyeDecide among the best the iPad / iPhone apps in its App Store Rewind 2011. It is interesting to think about the different places, and there are many, they could go from here.
Orca Health was among those selected for the StartUp Mobile Health Pavilion at the recent mHealth Summit (check out our full coverage), along with about two dozen other great mobile healthcare companies. There, I got to meet CEO & founder Matt Berry and publicist whiz Jake Lybbert (follow on Twitter). I talked with Matt about the (short) history and future of Orca Health, and his thoughts on the potential for tablets to improve the patient experience.
First, I have to ask – why the name Orca? Read more »
*This blog post was originally published at iMedicalApps*
The third edition of The Case for Personalized Medicine (PDF) was released a week ago and I had a chance to do an interview with Edward Abrahams, Ph.D. of the Personalized Medicine Coalition. The new edition is a primer that highlights the progress in the field of personalized medicine for policymakers, researchers, and business leaders.
- How many prominent examples of personalized medicine might we have next year?
It’s impossible for us to know how many prominent examples of personalized medicine products will be available a year from now, but we project that the rapid acceleration in the number of new products coming onto the market will continue. When we published the first edition of The Case for Personalized Medicine in 2006 – there were only 13 available products; when we published the second edition in 2009, there were 37 products available, and now, in 2011, there are 72.
- Sometimes lecturers use two numbers: 7 billion and 3 billion referring to the mass sequencing of everyone’s DNA in the world. When could it happen, what is your estimation? Read more »
*This blog post was originally published at ScienceRoll*
The Diabetes Research Institute is one of those places that, walking through its halls, you feel inspired. (I feel the same way when I walk through the Joslin Clinic in Boston – true diabetes magic happening there.) The people there are focused solely on finding a cure for diabetes, and that’s a mission I can truly get behind. Today, the DRI’s Tom Karlya is sharing some information on the Reason to Believe campaign.
* * *
Kerri: Hi Tom! You and I have worked together in the past, and I’m very familiar with your passion for finding a cure for this disease that both your kids and I share. For those who don’t know, what is the Diabetes Research Institute and what is your role there?
Tom: Thanks Kerri, over the years it has been exciting to work alongside you to help the diabetes community.
The DRI is the largest and most comprehensive research center in the world with a multidisciplinary team of scientists passionately committed to curing diabetes in the fastest, safest and most efficient way possible. We are solely dedicated to curing diabetes by finding a biological cure – restoring natural insulin production in patients. This has been and will continue to be our singular focus until that goal is reached. And it will be reached.
Kerri: I’ve heard a lot about the Diabetes Diplomats, and I know that outreach effort has engaged an amazing group of people. Who are the Diabetes Diplomats, and what are they all about? Read more »
*This blog post was originally published at Six Until Me.*
Dr. Eric Topol
It is hard to easily comprehend the depth and breadth of Dr. Topol’s career. He has been a major figure in cardiology, genomics and wireless health while also assuming leadership positions in landmark institutions such as the Cleveland Clinic and the Scripps Institute in La Jolla.
As chairman of cardiology at the Cleveland Clinic, he led the program to become number one for heart care. He was lead investigator on numerous national & worldwide cardiovascular clinical trials and started a medical school at the Clinic. He was also among the first physicians nationwide to call attention to the potential cardiac dangers of Vioxx. His very public criticism of Merck and the FDA brought to light the intimate but not always visible connections between the pharmaceutical industry and academic medicine.
Later he moved to San Diego, where he currently serves as director of the Scripps Translational Science Institute, Chief Academic Officer for Scripps Health and Professor of Translational Genomics. He has been a leading proponent of wireless medicine for more than a decade. He co-founded the West Wireless Health Institute with Gary and Mary West who contributed the initial $45m gift to start the Institute and have since committed an additional $100m to found a not-for-profit venture fund for wireless health companies. He currently serves as Vice Chairman of the Institute which is dedicated to “innovating, validating, and advocating for the use of technologies including wireless medical devices to transform medicine.” Be sure to check out our recent interview of WWHI chief executive Don Casey.
Dr. Topol is delivering the opening keynote for the mHealth Summit on December 5. His new book “The Creative Destruction of Medicine” is also making its debut at the Summit as an e-book, available to meeting attendees. Read below to hear his thoughts on the mHealth Summit and wireless platforms’ potential to improve health & transform the practice of medicine.
Why are you participating in the mHealth Summit? Read more »
*This blog post was originally published at iMedicalApps*
There has been an ongoing debate about placebos on SBM, both in the articles and in the comments. What does it mean that a treatment has been shown to be “no better than placebo?” If our goal is for patients to feel better and they feel better with placebos, why not prescribe them? Do placebos actually do anything useful? What can science tell us about why a patient might report diminished pain after taking an inert sugar pill? The subject is complex and prone to misconceptions. A recent podcast interview offers a breakthrough in understanding.
On her Brain Science Podcast Dr. Ginger Campbell interviewed Dr. Fabrizio Benedetti, a physician and clinical neurophysiologist who is one of the world’s leading researchers on the neurobiology of placebos. A transcript of the interview [PDF] is available on her website for those who prefer reading to listening. The information Dr. Benedetti presents and the expanded remarks by Dr. Campbell after the interview go a long way towards explaining the placebo phenomenon and its consequences for clinical medicine. Dr. Campbell also includes a handy list of references. I’ll try to provide a summary of the main points, but I recommend reading or listening to the original.
A common misconception is that Read more »
*This blog post was originally published at Science-Based Medicine*